Information Provided By:
Fly News Breaks for February 12, 2020
Feb 12, 2020 | 17:59 EDT
Goldman Sachs analyst Amit Hazan initiated coverage of Baxter with a Buy rating and $104 price target. The analyst contends that the renal tailwinds for the company will take some time and that its new EO and THERANOVA launch and reimbursement should generate increased growth for Baxter. While he estimates a growth rate of "only" 4.5% in 2020 and 2021, he also believes that the forecast has some upside potential.
News For BAX From the Last 2 Days
There are no results for your query BAX